To date, research into PI3K/AKT/mTOR signaling pathway inhibitors is still currently in progress, and it exhibits great positive significance to investigate the interaction between PD-L1 expression and PI3K/AKT/mTOR signaling pathway activation for addressing anticancer drug resistance, prolonging tumor patient survival, and improving patient prognosis. The gene discussed is PIK3CA; the disease is neoplasm.